Today's Rundown GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners [Sponsored] Salesforce proactively helps providers re-engage patients and reschedule elective procedures and services delayed by the COVID-19 crisis FAH to Senate: Pass more funding for providers now, change advance payment program Trial disruption 'likely to continue,' but 130 trials are now back up and running: report Roche hooks up with Gilead for Actemra-remdesivir combo trial in COVID-19 Here are 6 factors to consider—from legal issues to privacy protocols—when reopening practices FDA greenlights ICU AI for predicting fatal COVID-19 complications Biopharma roundup: Moderna deals with CordenPharma to acquire ingredients for mRNA vaccine Pharma's reputation is holding strong during COVID-19—and Harris Poll has some reasons Primary care practices could close in a matter of 'weeks not months' without financial support After passing safety hurdle, Orpheris kick-starts COVID-19 cytokine storm efficacy test Poll: Medicare Advantage members are taking to telehealth AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica production deal Uninsured new mothers face plenty of health challenges. COVID-19 could make that worse PureTech eyes clinical trial in long-term COVID-19 complications Featured Story | | | Thursday, May 28, 2020 GlaxoSmithKline has penned deals offering its pandemic vaccine adjuvant to several developers of COVID-19 shots. And it needs to amp up supply for those companies to make enough doses of their final products—to the tune of 1 billion doses. |
|
|---|
|
| | | Monday, May 25, 2020 Many elective procedures were postponed due to COVID-19, but with the Salesforce Accelerate Elective Procedures solution, providers are able to re-engage patients and reschedule elective procedures. |
|
|---|
|
Top Stories Thursday, May 28, 2020 The Federation of American Hospitals is calling on the Senate to adopt the House's massive stimulus package and to make changes to the Medicare Advance and Accelerated Payments Program. Thursday, May 28, 2020 There’s a mixed picture on clinical trials right now: While more and more tests are getting back on track after the pandemic delays, the “overall disruption of trials continues to expand.” Thursday, May 28, 2020 Roche is boosting its profile in COVID-19 by testing a combination of its rheumatoid arthritis drug Actemra with Gilead's antiviral remdesivir in patients with severe pneumonia. It's the latest in a string of COVID-19 initiatives from Roche, which is also researching a vaccine and has sped diagnostics to market. Thursday, May 28, 2020 As thousands of physicians are working to get their practices up and running again many are thinking about safety measures to keep patients and employees safe. But what about potential medical malpractice risks and privacy protocols? The American Medical Association offers a checklist to help practices reopen. Thursday, May 28, 2020 The FDA granted an emergency authorization to CLEW Medical’s remote data monitoring system to help predict and identify COVID-19 patients under intensive care who are most at risk for respiratory failure or insufficient blood flow. Thursday, May 28, 2020 AstraZeneca penned a deal with Oxford Biomedica to set the stage for COVID-19 vaccine supply. Roche started a phase III trial of its drug Actemra alongside Gilead's remdesivir to treat the virus. GSK pledged 1 billion adjuvant doses. And more. Thursday, May 28, 2020 Pharma’s reputation is holding strong these days, the latest Harris Poll survey shows. That’s good news again for the industry—but why the change? Perhaps unsurprisingly, 70% of Americans told the market researcher that the industry’s response to the COVID-19 crisis is the main reason for more positive feelings. Thursday, May 28, 2020 Without immediate financial support, a large number of primary care practices could close in a matter of weeks as a result of the strain from the COVID-19 pandemic, industry stakeholders say. Some financial support is making its way to primary care, but not enough. Thursday, May 28, 2020 Biotech Orpheris, one of the companies out of California pipeline play company Ashvattha Therapeutics has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19. Wednesday, May 27, 2020 A new poll found that roughly half of seniors are comfortable using telehealth to get healthcare, and those that do largely say they had a favorable experience. Thursday, May 28, 2020 AstraZeneca is on the hook for millions of doses of the University of Oxford's front-runner COVID-19 vaccine candidate, assuming it proves effective. To fulfill those orders, the British drugmaker has agreed to a short-term manufacturing deal that will help it bridge the gap. Thursday, May 28, 2020 New mothers face significant challenges when they lack health coverage—a concern the industry should be watching as the COVID-19 pandemic continues, researchers say. Thursday, May 28, 2020 PureTech is repositioning an antifibrotic drug for use in the treatment of long-term lung dysfunction associated with COVID-19. The Boston-based biotech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter. |
